KLP Kapitalforvaltning AS Invests $10.63 Million in Humana Inc. (NYSE:HUM)

KLP Kapitalforvaltning AS bought a new position in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 41,770 shares of the insurance provider's stock, valued at approximately $10,629,000.

A number of other large investors also recently added to or reduced their stakes in HUM. FPC Investment Advisory Inc. purchased a new position in shares of Humana in the fourth quarter worth about $27,000. Centricity Wealth Management LLC purchased a new position in Humana in the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA lifted its position in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana during the fourth quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. grew its holdings in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock worth $39,000 after purchasing an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.37% of the company's stock.

Remove Ads

Humana Stock Performance

NYSE HUM traded down $6.43 during trading hours on Friday, hitting $263.95. The company's stock had a trading volume of 967,907 shares, compared to its average volume of 1,758,856. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company's 50 day simple moving average is $270.14 and its two-hundred day simple moving average is $274.38. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market cap of $31.86 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana's payout ratio is 35.58%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Morgan Stanley dropped their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Barclays raised their target price on shares of Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Humana presently has a consensus rating of "Hold" and a consensus price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.